IASO107 / IASO BIO - LARVOL DELTA

IASO Biotechnology Announces Acquisition of Singapore-Based Cell Therapy Company MediSix Therapeutics (PRNewswire) - "This acquisition marks a step in IASO Bio's globalization strategy, integrating MediSix's differentiated T-cell engineering platform, R&D pipeline, and international talent IASO Bio's cell therapy. manufacturing and commercialization capabilities to further strengthen and accelerate its global R&D and operational systems....MediSix has also developed a differentiated pipeline addressing multiple unmet clinical needs. Its lead programme, IASO107 (formerly PCART7), is undergoing clinical evaluation in collaboration with leading international recognized research hospitals, and early clinical experience has shown promising efficacy and safety signals."

M&A • Oncology

Fratricide-resistant anti-CD7 CAR-T cells for relapsed/refractory Acute Myeloid Leukemia (ASH 2025) - "Pt#1 is a 19-year-old male with t(10; 17)(p15; q21) AML, relapsed 13 months after initial diagnosis, who failed second-line therapy including FLA, gemtuzumab-ozogamicin, Venetoclax, and progressed after bridging therapy with 5-Azacytidine/Venetoclax...Both patients received a single infusion of PCART7 (1x10 6 CAR-T cells/kg) following cyclophosphamide/fludarabine-based lymphodepletion...Conclusion This is the first demonstration that PCART7 may represent a valuable and feasible option for patients with r/r AML and high CD7 expression, offering the potential to achieve MRD-negative CR. The safety profile of the treatment is favorable and both T and NK cells CD7 negative can contribute to protect patients against infections."

CAR T-Cell Therapy • IO biomarker • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia • Respiratory Diseases • T Acute Lymphoblastic Leukemia • T-cell Acute Lymphoblastic Lymphoma • CD4 • CD8 • CRP

"Emerging Counter Stocks" Lejia Regeneration joins hands with Singapore's MediSix to jointly develop top-notch CAR-T therapy [Google translation] (stock.yahoo) - P=NA | N=NA | "Currently, MediSix's product with the fastest progress is PCART 7, which has been used for clinical treatment in Singapore and Italy respectively and completed proof of concept trials. The former has treated 12 patients with T-cell acute lymphoblastic leukemia (T-ALL), and the latter has treated 11 patients. 22 of the 23 patients had no detectable cancer cells in their blood 28 days after treatment, and achieved complete remission 28 days after the reinfusion of CAR-T cells, with only mild cytokine release syndrome and neurotoxicity occurring, and the treatment effect was good."

Clinical data • Cytokine release syndrome • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • T Acute Lymphoblastic Leukemia

"Emerging Counter Stocks" Lejia Regeneration joins hands with Singapore's MediSix to jointly develop top-notch CAR-T therapy [Google translation] (stock.yahoo) - "Lejia Regeneration...has cooperated with Singapore MediSix Therapeutics Pte. Ltd. In the future, Medisix’s leading projects will be CD7-targeted CAR-T products and PEBL patents that can control protein expression, will cooperate with Lejia to conduct manufacturing and clinical trials of Medisix's CAR-T cells. The two parties will also cooperate to establish a global 'clinical' R&D center in Taiwan to treat T-cell tumors and autoimmune diseases, making Lejia the CAR of Asia R&D and manufacturing center....MediSix plans to complete the Phase II clinical trial of PCART 7 for the treatment of T-cell tumors in Europe in the first quarter of 2026, and conduct some clinical trials for the treatment of autoimmune diseases."

Licensing / partnership • Trial completion date • Immunology • Oncology • Solid Tumor

Development of an Off-the-Shelf Chimeric Antigen Receptor (CAR)-T Cell Therapy for T-Cell Acute Lymphoblastic Leukemia (T-ALL) without Gene Editing (ASH 2022) - "We developed an anti-CD7 CAR-T cell product (PCART7) by utilizing a CD7 protein expression blocker (PEBL) to downregulate CD7 surface expression and prevent fratricide...The use of PEBL technology to generate allogeneic anti-CD7 CAR-T cells fits seamlessly in cGMP manufacturing protocols and avoids the risk of genotoxicity arising from the use of gene-editing techniques. Because the resulting allogeneic anti-CD7 CAR-T cells had high potency and were devoid of alloreactivity potential, they represent an attractive new tool for off-the-shelf CAR-T cell therapy of T-ALL and other CD7+ malignancies."

IO biomarker • Acute Lymphocytic Leukemia • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Lymphoma • Oncology • T Acute Lymphoblastic Leukemia • Transplantation